Vales-Villamarín Claudia, de Dios Olaya, Pérez-Nadador Iris, Gavela-Pérez Teresa, Soriano-Guillén Leandro, Garcés Carmen
Lipid Research Laboratory, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain.
Department of Pediatrics, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain.
Front Pharmacol. 2021 Nov 23;12:763853. doi: 10.3389/fphar.2021.763853. eCollection 2021.
Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated nuclear receptor that regulates glucose and lipid metabolism. Pharmacological activators of PPARγ are being used as a treatment of obesity related disorders such as dyslipidaemia and type 2 diabetes, but questions remain open regarding the effects of PPARγ on traits related to the development of type 2 diabetes. In our study, we have analyzed the relationship of the common variant Pro12Ala in the human PPARγ2 gene with the presence of obesity and with insulin, HOMA and lipid profile in a representative sample of 6-to 8-year-old children free from the confounding factors associated with adults. We found that Ala12Ala genotype was significantly more frequent in females with obesity than in those without obesity, with Ala12Ala carriers having significantly higher weight and body mass index (BMI), however the association disappeared when adjusting by leptin concentrations. The Ala12Ala genotype was associated with significantly higher HDL-cholesterol and apoA-I levels in males but not in females, independently of BMI. In a recessive model, in females, leptin levels appeared higher in Ala12Ala carriers. Although no apparent differences were observed in any sex when analyzing insulin levels and HOMA among genotypes without adjusting, lower insulin levels and lower HOMA appeared associated with Ala12Ala carriers when adjusting for BMI and leptin levels. In summary, our data showed that leptin seems to be having an effect on the association between the PPARγ2 Pro12Ala and BMI. Besides, after controlling for BMI and leptin, a protective effect of the Ala12Ala variant of the PPARγ2 Pro12Ala polymorphism on insulin sensitivity is evident already in prepubertal children.
过氧化物酶体增殖物激活受体γ(PPARγ)是一种配体激活的核受体,可调节葡萄糖和脂质代谢。PPARγ的药理激活剂正被用于治疗与肥胖相关的疾病,如血脂异常和2型糖尿病,但PPARγ对与2型糖尿病发展相关特征的影响仍不明确。在我们的研究中,我们分析了人类PPARγ2基因中常见的Pro12Ala变异与肥胖的存在以及胰岛素、稳态模型评估胰岛素抵抗(HOMA)和血脂谱之间的关系,研究对象为6至8岁、无成人相关混杂因素的代表性儿童样本。我们发现,肥胖女性中Ala12Ala基因型的频率显著高于非肥胖女性,Ala12Ala携带者的体重和体重指数(BMI)显著更高,然而在根据瘦素浓度进行校正后,这种关联消失了。Ala12Ala基因型与男性较高的高密度脂蛋白胆固醇(HDL-胆固醇)和载脂蛋白A-I水平相关,而与女性无关,且不受BMI影响。在隐性模型中,女性Ala12Ala携带者的瘦素水平似乎更高。在未校正的情况下分析各基因型之间的胰岛素水平和HOMA时,未观察到明显的性别差异,但在校正BMI和瘦素水平后,较低的胰岛素水平和较低的HOMA似乎与Ala12Ala携带者相关。总之,我们的数据表明,瘦素似乎对PPARγ2 Pro12Ala与BMI之间的关联有影响。此外,在控制BMI和瘦素后,PPARγ2 Pro12Ala多态性的Ala12Ala变异对青春期前儿童胰岛素敏感性的保护作用已经很明显。